

**- Effectiveness of pegylated interferon/ribavirin combination in "real world" patients with chronic hepatitis C virus infection**

G. Borroni, M. Andreoletti, M.A. Casiraghi, R. Ceriani, P. Guerzoni, B. Omazzi, N. Terreni, F. Salerno

Aliment Pharmacol Ther 2008; 27, 790-797

**- Neutropenia and infectious complications during combination therapy for chronic hepatitis C**

G. Borroni, M. Andreoletti, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, B. Omazzi, N. Terreni, G. Spinzi

Gut 2008; 57 ( Suppl II ), A290, P0928

**- Exposure to ribavirin but no HCV genotypes affect response to treatment with PEG interferon and ribavirin in HCV genotype 2 or 3**

G. Borroni, M. Andreoletti, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, B. Omazzi, N. Terreni, G. Spinzi

Gut 2008; 57 ( Suppl II ), A290, P0929

**- Treatment discontinuation and dose reduction of pegylated interferon/ribavirin combination therapy in patients with chronic hepatitis C**

G. Borroni, M. Andreoletti, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, B. Omazzi, N. Terreni, G. Spinzi

Gut 2008; 57 ( Suppl II ), A290, P0930

**- Association between transarterial embolization and radiothermal ablation in the treatment of large hepatocellular carcinoma**

Gianquinto G., Guerzoni P., Millefanti L., Chianese G., Segato S., Recaldini C., Laganà D. and Carraffiello G.

Digestive and Liver Disease 2008 ;40 Suppl.1 :S125

**- International guidelines and management of chronic hepatitis C ( CHC) treatment in clinical practice**

G. Borroni, M. Andreoletti, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, S. Paggi, A. Prada, G. Spinzi, N. Terreni

Dig Liv Dis Vol 41S ( 2009) S112

**- Retrospective analysis of the efficacy of PEG-IFN alfa 2 b vs PEG-IFN alfa 2 a plus ribavirin in treatment naïve chronic HCV patients**

N. Terreni, M. Andreoletti, G. Borroni, A. Bortoli, M.A. Casiraghi, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, S. Paggi, A. Prada, G. Spinzi

Dig Liv Dis Vol 41S ( 2009) S113

**- Hemoglobin decline is not associated with SVR among HCV G1-infected patients in day to day clinical practice**

G. Spinzi, G. Borroni, M. Andreoletti, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, S. Paggi, N. Terreni  
Hepatol. Oct.2009 696A

**- Decline in hemoglobin concentration and neutrophil count is not associated with the likelihood of SVR in Genotype 1 chronic hepatitis patients**

G. Borroni, M. Andreoletti, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, B. Omazzi, S. Paggi, M.G.L. Pich, A. Prada, G. Spinzi, N. Terreni  
Dig Liv Dis 2010 ;42 S2 P232

**- The impact of age on response to therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis C**

G. Spinzi, M. Andreoletti, G. Borroni, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, M.G.L. Pich, A. Prada, N. Terreni  
Gut 2010 ;59 (Suppl III) A 435

**- Infection and neutropenia during PEG Interferon / Ribavirin therapy in patients with chronic hepatitis C**

G. Spinzi, M. Andreoletti, G. Borroni, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, M.G.L. Pich, A. Prada, N. Terreni  
Dig Liv Dis 2011 ;43 S3 :P 204

**- Reduced renal function is associated with anemia during treatment with Peginterferon // ribavirin in elderly chronic hepatitis C patients**

R. Ceriani, M. Andreoletti, G. Borroni, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, P. Guerzoni, G. Mandelli, B. Omazzi, M.G.L. Pich, A. Prada, N. Terreni, G. Spinzi  
Dig Liv Dis 2011 ;43 S3 :P 41

**- In CHC patients aged  $\geq 50$  yeras ribavirin-induced anemia depends on renal function**

G. Borroni, M. Andreoletti, A. Bortoli, M.A. Casiraghi, M. Cazzaniga, R. Ceriani, P. Guerzoni, G. Mandelli, B. Omazzi, M.G.L. Pich, A. Prada, G. Spinzi, N. Terreni  
Dig Liv Dis 2011; 43 Suppl 2, Page S88